Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum

Nucleic Acid Therapeutics

Volumn 24, Issue 5, 2014, Pages 326-335

  Henry, Scott P ^a   Jagels, Mark A ^b   Hugli, Tony E ^b   Manalili, Sheri ^a   Geary, Richard S ^a   Giclas, Patricia C ^c   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT FACTOR H; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; ZYMOSAN; ANTISENSE OLIGODEOXYNUCLEOTIDE; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; DRUG MECHANISM; EXPERIMENTAL DOG; HUMAN; IMMUNE DEFICIENCY; IMMUNOASSAY; IN VITRO STUDY; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN BINDING; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; SURFACE PLASMON RESONANCE; ANIMAL; BLOOD; CHEMISTRY; DOG; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA FASCICULARIS; METABOLISM; RHESUS MONKEY; SPECIES DIFFERENCE;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; DOGS; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MACACA MULATTA; MALE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PROTEIN BINDING; SPECIES SPECIFICITY;

EID: 84907045407     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0491     Document Type: Article

References (34)

1. Crooke ST. (1996). Therapeutic applications of oligonu-cleotides in medicine. Chem Ind 3:90-93.
2. Crooke ST. (1996). Progress in antisense therapeutics. Med Res Rev 16:319-344.
3. Bennett CF. (1998). Antisense oligonucleotides: is the glass half full or half empty? Biochem Pharmacol 55:9-19.
4. Henry SP, D Monteith and AA Levin. (1997). Antisense oli-gonucleotide inhibitors for the treatment of cancer: 2. Toxi-cologic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:395-408.
5. Levin AA, DK Monteith, JM Leeds, PL Nicklin, RS Geary, M Butler, MV Templin and SP Henry. (1998). Toxicity of oligodeoxynucleotide therapeutic agents. In: Antisense Research and Application. ST Crooke, ed. Springer, Heidelberg, pp 169-215.
6. Agrawal S, J Goodchild, MP Civeira, AH Thornton, PS Sarin and PC Zamecnik. (1988). Oligodeoxynucleoside phosphoramidites and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci (USA) 85:7079-7083.
7. Geary RS, JM Leeds, SP Henry, DK Monteith and AA Levin. (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phos-phorothioate oligodeoxynucleotides. Anticancer Drug Des 12:383-393.
8. Henry SP, PC Giclas, J Leeds, M Pangburn, C Auletta, AA Levin and DJ Kornbrust. (1997). Activation of the alternative pathway of complement by a phosphorothioate oli-gonucleotide: Potential mechanism of action. J Pharmacol Exp Ther 281:810-816.
9. Henry SP, W Novotny, J Leeds, C Auletta and DJ Kornbrust. (1997). Inhibition of coagulation by a phosphor-othioate oligonucleotide. Antisense Nucleic Acid Drug Dev 7:503-510.
10. Galbraith WM, WC Hobson, PC Giclas, PJ Schechter and S Agrawal. (1994). Complement activation and hemody-namic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201-206.
11. Henry SP, J Taylor, L Midgley, AA Levin and DJ Kornbrust. (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev 7:473-481.
12. Levin AA, RS Geary, JM Leeds, DK Monteith, RZ Yu, MV Templin and SP Henry. (1998). The pharmacokinetics and toxicity of phosphorothioate oligonucleotides. In: Biotechnology and Safety Assessment. JA Thomas, ed. Taylor & Francis, Philadelphia, PA, pp 151-175.
13. Sarmiento UM, JR Perez, JM Becker and N Ramaswamy. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev 4: 99-107.
14. Beaucage SL and RP Iyer. (1992). Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron 48:2223-2311.
15. Harbeck RJ and PC Giclas. (1991). Complement levels by radialimmunodiffusion. In: Diagnostic Immunology Laboratory Manual. Raven Press, New York, NY, pp 9-20.
16. Keil LB, E Jimenez, M Guma, MD Reyes, C Liguori and VA DeBari. (1995). Biphasic response of complement to heparin: fluid-phase generation of neoantigens in human serum and in a reconstituted alternative pathway amplification cycle. Am J Hematol 50:254-262.
17. Leeds JM, MJ Graham, L Troung and LL Cummins. (1996). Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36-43.
18. Weiler JM, RW Yurt, DT Fearon and KF Austen. (1978). Modulation of the formation of the amplification con-vertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 147:409-421.
19. Srinivasan SK, HK Tewary and PL Iversen. (1995). Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 5:131-139.
20. Brown DA, SH Kang, SM Gryaznov, L DeDionisio, O Heidenreich, S Sullivan, X Xu and MI Nerenberg. (1994). Effect of phosphorothioate modification of oligodeoxynuc-leotides on specific protein binding. J Biol Chem 269:26801-26805.
21. Henry SP, D Monteith, F Bennett and AA Levin. (1997). Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12: 409-420.
22. Henry SP, JE Zuckerman, J Rojko, WC Hall, RJ Harman, D Kitchen and ST Crooke. (1997). Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des 12:1-14.
23. Henry SP, R Larkin, WF Novotny and DJ Kornbrust. (1994). Effects of ISIS 2302, a phosphorothioate oligonu-cleotide, on in vitro and in vivo coagulation parameters. Plenum Press, New York, London, pp S-353.
24. Dorr FA and DL Kisner. (1998). Antisense oligonucleo-tides to protein kinase C-a and C-raf kinase: rationale and clinical experience in patients with solid tumors. In: Antisense Research and Application. ST Crooke, ed. SpringerVerlag, Heidelberg, pp 463-476.
25. Bitter-Suermann D, R Burger and U Hadding. (1981). Activation of the alternative pathway of complement: efficient fluid-phase amplification by blockade of the regulatory complement protein b1h through sulfated polyanions. Eur J Immunol 11:291-295.
26. Boackle RJ, GB Caughman, J Vesely, G Medgyesi and H Fudenberg. (1983). Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol Immunol 20:1157-1164.
27. Schreiber RD, MK Pangburn, PH Lesavre and HJ MullerEberhard. (1978). Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci (USA) 75:3948-3952.
28. Kazatchkine MD, DT Fearon and KF Austen. (1979). Human alternative complement pathway: membrane associated sialic acid regulates the competition between B and B1H for cell-bound C3b. J Immunol 122:75-81.
29. Edens RE, RJ Linhardt, CS Bell and JM Weiler. (1994). Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immuno-pharmacology 27:145-153.
30. Meri S and MK Pangburn. (1990). Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci (USA) 87:3982-3986.
31. Pangburn MK and HJ Muller-Eberhard. (1984). The alternative pathway of complement. Springer Semin Immuno-pathol 7:163-192.
32. Pangburn MK, MA Atkinson and S Meri. (1991). Localization of the heparin binding site on complement factor H. J Biol Chem 266:16847-16853.
33. Gardner WD, PJ White and SO Hoch. (1980). Identification of a major human serum DNA-protein as b1h of the alternative pathway of complement activation. Biochem Biophys Res Commun 94:61-67.
34. Maillet F, MD Kazatchkine, D Glotz, E Fischer and M Rowe. (1983). Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 20:1401-1404.